A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Safety and Efficacy of LX3305, a Sphingosine-1-Phosphate Lyase Inhibitor, for Treatment of Darier's Disease or Hailey-Hailey Disease
Latest Information Update: 04 Apr 2022
At a glance
- Drugs ACB2003.4 (Primary)
- Indications Benign Familial Pemphigus; Darier disease; Skin disorders
- Focus Adverse reactions
- Sponsors Dermecular Therapeutics
- 02 Apr 2022 Status changed from recruiting to completed.
- 28 Jun 2018 New trial record